CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 92 enrolled
Drug / intervention
Risperidone, administered orally (Oral Ris) +3 moredrug
Likely dose
Risperidone, administered via injection (RLAI) 25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00333177
NCT00333177Phase 4Completed
CompareCT.gov

Developmental Processes in Schizophrenic Disorders: Cognitive Remediation, Medication Adherence, and Work Outcome in Recent-Onset Schizophrenia

University of California, Los Angeles·interventional·Posted Jun 2, 2006·Updated Mar 26, 2020

In Brief

A Phase 4 clinical trial evaluating Cognitive remediation training (CT), Healthy behavior training (HBT), and 2 other interventions for Schizophrenia. Completed, enrolled 92 participants across 1 site.

Detailed Summary

This study will determine the effectiveness of various combinations of psychosocial therapy and risperidone treatment in improving work or school performance in people with first-episode schizophrenia.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
CountriesUnited States
CollaboratorsNational Institute of Mental Health (NIMH), Janssen Scientific Affairs, LLC

Timeline

Phase 4CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 2, 2006
Enrollment StartMar 1, 2006
Primary CompletionJan 1, 2013
TodayJul 2, 2026
Enrollment to primary: 6.8 yearsPosted 20.1 years ago

Interventions

Cognitive remediation training (CT)behavioral

Cognitive remediation training includes computerized cognitive training plus learning skills group.

Healthy behavior training (HBT)behavioral

Healthy behavior training includes group skills training in nutrition, exercise, and relaxation.

Risperidone, administered orally (Oral Ris)drug

Oral risperidone at dosage judged optimal by treating psychiatrist

Risperidone, administered via injection (RLAI)drug

Risperidone in injectable form every 2 weeks, starting with 25 mg and adjusted as needed